Company Overview and News
· The global nanomedicine market is anticipated to reach USD 350.8 billion by 2025, according to a new report by Grand View Research, Inc.
RnRMarketResearch.com adds "Bone Metastasis - Pipeline Review, H1 2017" therapeutic market research report of 100 pages with latest updates, data and information to its online business intelligence library.
Good morning, ladies and gentlemen. It’s a pleasure to be with you here this morning and great to see you in full of Analysts and Investor interest in the ongoing Vectura. Welcome to those who listening on the telephone or on the webcast.
Chippenham, UK - 23 November 2016: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading device and formulation business for inhaled airways products, today announces its unaudited interim results for the six months ended 30 September 2016.
The following slide deck was published by Ablynx NV in conjunction with their 2016 Q2 earnings call.
I am a fervent believer that investors are best served by investing towards a specific investment objective that suits their own unique goals, objectives and risk tolerance. In other words, investing is not always trying to get the highest possible total returns. If that were true, no one would have ever invested in bonds, CDs or other fixed income instruments.
Ablynx NV (OTC:ABLYF) Results from first-in-infant study with inhaled ALX-0171 for the treatment of RSV infections Presentation Call May 3, 2016 10:00 AM ET
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Ablynx NV (OTC:ABLYF) Q4 2015 Earnings Conference Call February 25, 2016 09:00 AM ET Executives Edwin Moses - Chief Executive Officer Wim Ottevaere - Chief Fina
PUNE, India, February 18, 2016 /PRNewswire/ -- New market research titled
As filed with the Securities and Exchange Commission on January 22, 2016 Registration No. 333-208918 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENSPERA, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-0438951 (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.